ANI Pharmaceuticals price target raised to $80 from $72 at Truist

Truist raised the firm’s price target on ANI Pharmaceuticals to $80 from $72 and keeps a Buy rating on the shares. The company reported another strong quarter, driven by continued Cortrophin uptake and generics growth on higher volume and product launches, the analyst tells investors in a research note. The frequency of competitor disruptions have somewhat eased, though the management expects high-single to low-double digit growth for the GX segment, the firm added.